When a therapeutic program calls for a dedicated company, CD3 partners in the creation of a spin-off. This gives promising science, often originating from academic research, the opportunity to advance within a focused and purpose-built organization, supported by both capital and ongoing scientific guidance.

This route is chosen deliberately when the science, team, and development path benefit from a standalone structure rather than direct outlicensing. For founders and researchers, it offers the chance to build and grow a company around their innovation, while staying closely supported through key development stages.

This approach has led to several active spin-offs:

• Rewind Therapeutics — developing a treatment for multiple sclerosis
• Cytura Therapeutics — a cancer therapy targeting genomic instability
• HDC — state-of-the-art high-throughput screening

Considering a spin-off from your research program?